title: Acute coronary syndromes: targeting inflammation-what has the VISTA-16 trial taught us?
abstract: The VISTA-16 trial of varespladib, a secretory phospholipase A2 (sPLA2) inhibitor, in patients with an acute coronary syndrome was terminated prematurely owing to futility and a signal towards harm. Despite these discouraging results, therapies that target inflammation to modify pathways in atherogenesis remain an area of active investigation.
authors.affiliation: TIMI Study Group, Brigham and Women's Hospital, 350 Longwood Avenue, 1st Floor, Boston, MA 02115, USA.
authors.forename: Michelle L
authors.initials: ML
authors.lastname: O'Donoghue
mesh_terms: D000085:Acetates / Q000009:adverse effects* / Q000627:therapeutic use*; D054058:Acute Coronary Syndrome / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007211:Indoles / Q000009:adverse effects* / Q000627:therapeutic use*; D008297:Male; D009203:Myocardial Infarction; D010741:Phospholipases A / Q000037:antagonists & inhibitors*
chemical_list: D000085:Acetates; D007211:Indoles; D010741:Phospholipases A